JBMedical

@JBMedical3

We provide expert advice and support to achieve market access in pharmaceuticals, medical devices and other healthcare innovations

UK
Vrijeme pridruživanja: lipanj 2019.

Tweetovi

Blokirali ste korisnika/cu @JBMedical3

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @JBMedical3

  1. Prikvačeni tweet
    8. lis 2019.

    We are now a NICE MedTech Early Technical Assessment provider so we can help medtech clients to identify ways to optimise their development plans and potential next steps to bring their technology to market

    Poništi
  2. prije 13 sati

    Have complete brain ache after a couple of hours pulling together a Gantt chart for a NICE submission we are about to embark upon, need a lie down in a darkened room !

    Poništi
  3. prije 19 sati

    'Just as antibiotics were the miracle of the 20th century, exercise can be the 'miracle cure' of the 21st' - absolutely true, for both mental and physical health

    Poništi
  4. 4. velj

    On we are proud to have worked with pharma and device companies to gain HTA approval for their oncology products, giving patients access to new and innovative treatments for cancer

    Poništi
  5. 4. velj

    this is a useful resource - will be flicking through for a refresher

    Poništi
  6. 3. velj

    I love this, we can learn from everything, things that go well and those that don't. Plus isn't it beautiful ?

    Poništi
  7. 31. sij

    Finalising a NICE Scientific Advice Briefing Book for one of our clients today; early engagement with HTA bodies is a great way to help to frame market access plans

    Poništi
  8. 31. sij

    What a beautiful piece - and how tragic that it had to be made. Still can't believe that we are leaving Europe today, I hope with all my heart we find a way back

    Poništi
  9. 30. sij

    Busy week this week, reviewing our report on a systematic literature review and meta-analysis looking at data on the link between minimal residual disease and survival in haematological cancers

    Poništi
  10. 29. sij
    Poništi
  11. 29. sij

    Looking at position in the disease pathway and appropriate pricing points for a new formulation of an existing product this morning. Interesting work !

    Poništi
  12. 28. sij

    Heading out to a meeting to listen to feedback from market research on some value messages which we wrote last year, really interested to see how the messages have been received by payors and by clinicians in the NHS

    Poništi
  13. 28. sij

    definitely going to tune into this - using the right language is essential for good communication

    Poništi
  14. 27. sij

    Getting to grips with the clinical data for a new vaccine today as we prepare for a JCVI submission on behalf of one of our clients

    Poništi
  15. 24. sij

    Popped into this when I was in town today, great project showing people living with rare diseases in the UK. Loved it

    Poništi
  16. 23. sij

    Take a look at the 2020 Top 10 HEOR Trends report from ISPOR, each one is important to consider, but I think numbers 3 and 8 are particularly valid Find the report at via

    Poništi
  17. 23. sij

    A gentle morning after a hard day yesterday, pulling together a reference pack for a paper which we have written describing the most cost-effective patient populations for our client's product

    Poništi
  18. 22. sij

    Whilst some of us are at NICE the rest of the team are busy working on updating a model in atrial fibrillation and finalising a meta-analysis looking at minimal residual disease in haematological cancers

    Poništi
  19. 21. sij

    Love this idea, it's so important to reflect on our achievements (personally and professionally), also I❤️a list

    Poništi
  20. 21. sij
    Poništi
  21. 21. sij
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·